LimmaTech Biologics AG is applying its deep expertise in engineering complex carbohydrate molecules to develop next-generation vaccines to prevent life-threatening diseases. Spun out from GlycoVaxyn after that company was acquired by GSK, LimmaTech Bio is advancing its own proprietary clinical pipeline to halt the increasing threat of global infections due to emerging antimicrobial resistance and sexually transmitted infections such as gonorrhoea, alongside partnered programmes with GSK. LimmaTech is committed to translating novel scientific concepts into highly effective vaccines that benefit humanity.